What is Lassogen?
Lassogen is at the forefront of developing a new generation of medicines by optimizing lasso peptides, a class of molecules found in nature. Their core innovation, termed Lassotides, aims to offer a therapeutic modality that combines the favorable characteristics of both antibodies and small molecules, thereby addressing diseases that are currently difficult to treat. The company's foundation is built upon a robust scientific team with extensive collective experience spanning over a century in the biotech and pharmaceutical sectors. Lassogen is strategically targeting a wide array of disease indications with its unique and advanced therapeutic platform.
How much funding has Lassogen raised?
Lassogen has raised a total of $4.5M across 1 funding round:
Angel/Seed
$4.5M
Angel/Seed (2020): $4.5M with participation from Better Ventures, Playground Global LLC, Foothill Ventures, and First In Ventures
Key Investors in Lassogen
Better Ventures
Better Ventures is a mission-driven venture capital firm that invests in early-stage startups focusing on leveraging science and technology to create a sustainable economy that benefits people and the planet. Their investment themes include sustainable industry, improving human health, and equipping tomorrow's workforce, all aimed at addressing significant global challenges.
Playground Global LLC
Undisclosed investor participating in the funding round.
Foothill Ventures
Undisclosed investor participating in the funding round.
What's next for Lassogen?
With the recent major strategic investment, Lassogen is poised for significant growth and advancement in its research and development pipeline. The substantial capital infusion, part of its $4.5M in overall funding, will likely be directed towards expanding its clinical trials, enhancing its manufacturing capabilities, and further solidifying its intellectual property portfolio. This strategic financing signals strong confidence from investors in Lassogen's novel therapeutic modality and its potential to disrupt the treatment landscape for challenging diseases. The company's focus on programmable medicines derived from lasso peptides positions it as a key player in the future of biopharmaceutical innovation.
See full Lassogen company page
